Global As the focus of the global COVID-19 pandemic response shifts downstream from the development and production of vaccines to vaccination campaigns themselves, IFPMA Director-General Thomas Cueni lays out the biopharmaceutical industry’s three new overarching priorities: supporting country readiness, contributing to equitable distribution, and driving innovation. From the early days…
APAC Drawing on the findings of a recent report launched under the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and medium-sized enterprises (SMEs) of adopting ethical practices. Cueni highlights some of the key trends that emerged from report, conducted…
South Africa Kelly Chibale, founder of the H3D Centre at the University of Cape Town and chairman & CEO of the H3D Foundation, outlines the rationale behind the establishment of these institutions, the vital importance of health innovation in and for Africa, the potential impact of a new partnership with global pharma…
Global The World Health Assembly Special Session on a Pandemic Treaty, which will convene health ministries from around the world in Geneva next week, offers a unique opportunity to take a look back and share some important lessons learnt from fighting the COVID-19 pandemic. James Anderson, Executive Director, Global Health, at…
Global Paula Barbosa, head of influenza policy and advocacy at the IFPMA and board member of the #TogetherAgainstFlu campaign, looks ahead to what could be a devastating 2021/22 flu season, with natural immunity among vulnerable populations down following the pandemic induced lockdowns and preventive measures of last year. Barbosa lays out…
Global Pharma industry leaders have called for rich nations to stop stockpiling excess COVID-19 vaccine doses and stated that there will be enough production by the end of the year to cover the entire global population. The head of Pfizer, J&J, and industry association the IFPMA also hope that this surge…
Global Big Pharma’s representatives are warning of upcoming bottlenecks in the COVID-19 vaccine manufacturing supply chain and are asking for a unified approach to address inefficiencies and increase manufacturing capacities. However, recently published reports and news point to inefficiencies within the manufacturing industry itself and not necessarily a lack of raw…
Global The issue of COVID-19 vaccine access in developing nations has thrust intellectual property (IP) into global headlines. Against the backdrop of heated arguments both for and against an IP waiver for COVID-related products, the global pharma industry has launched a new initiative on IP, asserting its crucial importance to continued…
Global On World Intellectual Property (IP) Day 2021, the innovative biopharmaceutical industry came together to launch a new initiative foregrounding the benefits to patients and to society at large of a robust IP framework. Under the INTERPAT umbrella, 25 industry members and associations launched the ‘IP Principles for Advancing Cures and…
Global The global rush to secure access to COVID-19 vaccines has led to accusations that richer countries are hoarding supply at the expense of poorer nations. While some are calling for a relaxation of intellectual property (IP) to allow less-developed nations to vaccinate their populations, Big Pharma is resistant, arguing that…
Global Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19 vaccines from bench to market in less than a year and introduces the IFPMA’s new #TeamVaccines campaign, shedding light on the personal stories behind this miraculous effort. The story of COVID-19…
Coronavirus During the fourth International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) COVID-19 media briefing, one thematic dominated: collaboration. With Eli Lilly chairman and CEO David Ricks, also president of IFPMA; Roche CEO Dr Severin Schwan, also vice-president of IFPMA; Pfizer chairman and CEO Dr Albert Bourla; MSD (Merck & Co.…
See our Cookie Privacy Policy Here
